Two Different Meningioma Variants in the Same Tumor: A Rare Histopathological Finding

Khubrani, Reham; Al-Dandan, Sadeq

doi:10.1155/2019/8267163

Cited by 1 publication

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The meningothelial cell with lipomatous metaplasia exhibited immunoreactivity to Epithelial Membrane Antigen (EMA) in 37 cases (5, 7-10, 15,16, 23-28, 33, 35, 36), and Vimentin in 15 cases (5, 9, 10, 15, 16, 23-26, 28, 35-37). Ten meningiomas presented progesterone receptor (5,6,15,27,33,34,37), nine meningiomas showed S100-Protein (11,24,26,27,35,36), three meningiomas presented CD99 (27,37), three meningioma showed Cytokeratin (8,11,34), and two cases resulted positive for CEA (8,11).…”

Section: Assessment and Diagnosismentioning

confidence: 98%

“…Intraoperatively, the tumour has well-defined margins and a brown-yellowish appearance, with a visible adipocyte component. Histologically, it is composed of adipocyte-like cells within a conventional type meningioma (11). These adipocyte-like cells are elongated with tapered ends and round nuclei with eosinophilic cytoplasm.…”

Section: Assessment and Diagnosismentioning

confidence: 99%

“…EMA and VMT are distinctive markers for meningiomas that reflect epithelial and mesenchymal cells (30); markers of immunoreactivity such as EMA, VMT, S-100, and progesterone receptors confirm the meningothelial differentiation (27). Cases in which both secretory and lipidated cells are present, the hyaline inclusion bodies of the secretory type meningioma result positive for periodic acid Schiff (PAS) stain as well as carcinoembryonic antigen (CEA), with surrounding CK-positive tumour cells (11). The presence of fat tissue is definitively diagnosed with the histological and immunohistochemical examination.…”

Section: Assessment and Diagnosismentioning

confidence: 99%

“…in vivo 35: 3031-3037 (2021) 3034 Macroscopically, the lesions were yellowish, soft, and difficult to differentiate from adipose tissue. The different histological findings of lipomatous meningiomas are described as meningothelial meningiomas with a lipomatous component in 38% of cases, transitional meningiomas with a lipomatous component in 12% (7,25,27,32,33), secretory meningioma with a lipomatous component in 8% (8)(9)(10)(11)34), microcystic meningioma with a lipomatous component in 3% (7,27), and in only one case the histological diagnosis was Chordoid Meningioma with a lipomatous component (7). The meningothelial cell with lipomatous metaplasia exhibited immunoreactivity to Epithelial Membrane Antigen (EMA) in 37 cases (5, 7-10, 15,16, 23-28, 33, 35, 36), and Vimentin in 15 cases (5, 9, 10, 15, 16, 23-26, 28, 35-37).…”

Section: Assessment and Diagnosismentioning

confidence: 99%

See 3 more Smart Citations

Lipomatous Meningioma: Clinical-Pathological Findings, Imaging Characterisation and Correlations of a Rare Type of Meningioma

Lapolla

Familiari

Zancana

et al. 2021

In Vivo

View full text Add to dashboard Cite

Lipomatous meningioma (LM) is a form of metaplasia, originating from intracellular lipid bodies accumulation due to metabolic alterations. A comprehensive literature review was performed introducing further elements of evaluation. The parameters utilized were age, sex, location, clinical presentation, imaging features, treatment, and recurrences. Seizure and headache are the primary onsets of symptoms. Further LM clinical features, such as visual disturbances and visual epileptic seizures were examined. Symptoms may occur ten years prior to LM finding and it can resolve completely with the indicated surgery. LM computed tomography imaging analysis reveals hypodense regions due to the presence of fat content. On magnetic resonance imaging, the lesion displays hyperintense signal in T1-T2 with signal loss in the fatsuppression sequences. Immunohistochemically, lipidized meningioma cells are positive for Epithelial-Membrane Antigen, Vimentin, CD99, S-100 protein, and progesterone receptor. The recurrence risk rate of LM is estimated to be around 17%. Precise immune-histological findings have been correlated with imaging features to help with early diagnosis. A defined diagnosis of LM is a crucial factor in the choice of treatment.

show abstract